Evaluation of Endogenous Metabolic Markers of Hepatic CYP3A Activity Using Metabolic Profiling and Midazolam Clearance

4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo – effects of itraconazole in man

(2013) D. Lütjohann* et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Venous Hemangioma of Parapharyngeal Space with Calcification

(2011) Jung-Hae Cho et al.   Clinical and Experimental Otorhinolaryngology

Evaluation of 6β-Hydroxycortisol, 6β-Hydroxycortisone, and a Combination of the Two as Endogenous Probes for Inhibition of CYP3A4 In Vivo

(2011) C-C Peng et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmaco-metabolomics: An emerging “omics” tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets

(2011) Giuseppe Corona et al.   JOURNAL OF CELLULAR PHYSIOLOGY

4β-hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans

(2010) Ulf Diczfalusy et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Use of Pharmaco-Metabonomics for Early Prediction of Acetaminophen-Induced Hepatotoxicity in Humans

(2010) J H Winnike et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

An Integrative Approach for Identifying a Metabolic Phenotype Predictive of Individualized Pharmacokinetics of Tacrolimus

(2010) P B Phapale et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Evaluation of plasma enzyme activities using gas chromatography–mass spectrometry based steroid signatures

(2009) Young Wan Ha et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Heat-map visualization of gas chromatography-mass spectrometry based quantitative signatures on steroid metabolism

(2009) Ju-Yeon Moon et al.   JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY

Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism

(2009) T. A. Clayton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway

(2008) Kun Wang et al.   BIOCHEMICAL PHARMACOLOGY

4β-Hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin

(2008) Ulf Diczfalusy et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The CYP3A4*18 Genotype in the Cytochrome P450 3A4 Gene, a Rapid Metabolizer of Sex Steroids, Is Associated With Low Bone Mineral Density

(2008) YS Kang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Cytochrome P450 Induction by Rifampicin in Healthy Subjects: Determination Using the Karolinska Cocktail and the Endogenous CYP3A4 Marker 4β-Hydroxycholesterol

(2008) KP Kanebratt et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

4??-Hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians

(2008) Ulf Diczfalusy et al.   Pharmacogenetics and Genomics

The Tangle of Nuclear Receptors that Controls Xenobiotic Metabolism and Transport: Crosstalk and Consequences

(2007) Jean-Marc Pascussi et al.   Annual Review of Pharmacology and Toxicology